leadf
logo-loader
viewRedx Pharma PLC

Redx Pharma looks ahead to first in man clinical trials of its fibrosis drug RXC007

Redx Pharma Plc's (LON:REDX) chief scientific officer Richard Armer recaps on its RXC007 programme - a drug which has potential for development in multiple fibrotic conditions. He says they're currently carrying out manufacturing work and safety studies to build the regulatory package that should allow them to enter first in man clinical trials in the first half of 2021.

Quick facts: Redx Pharma PLC

Price: 66.5 GBX

AIM:REDX
Market: AIM
Market Cap: £129.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma PLC in a great place to move forward after Astra deal says CEO

Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel...

on 4/8/20

2 min read